Marker Therapeutics Stock Analysis

Marker Stock Analysis Notes

About 42.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.8. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Marker Therapeutics recorded a loss per share of 1.07. The entity last dividend was issued on the 16th of September 2016. The firm had 1:10 split on the 27th of January 2023. Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. The company was founded in 1999 and is headquartered in Houston, Texas. Marker Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. To find out more about Marker Therapeutics contact Peter MBA at 713 400 6400 or learn more at https://markertherapeutics.com.

Marker Therapeutics Investment Alerts

Marker Therapeutics Upcoming and Recent Events

Marker Largest EPS Surprises

View All Earnings Estimates

Marker Therapeutics Thematic Classifications

Marker Stock Institutional Investors

Note, although Marker Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Marker Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.39 M.

Marker Profitablity

The company has Profit Margin (PM) of (1.8) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.25) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.25.

Management Efficiency

Marker Therapeutics has return on total asset (ROA) of (0.4192) % which means that it has lost $0.4192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7976) %, meaning that it created substantial loss on money invested by shareholders. Marker Therapeutics' management efficiency ratios could be used to measure how well Marker Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/24/2025, Return On Tangible Assets is likely to drop to -0.77. In addition to that, Return On Capital Employed is likely to grow to -1.13. At this time, Marker Therapeutics' Other Current Assets are relatively stable compared to the past year. As of 03/24/2025, Net Tangible Assets is likely to grow to about 53.1 M, while Non Current Assets Total are likely to drop 0.00.

Technical Drivers

As of the 24th of March, Marker Therapeutics secures the Standard Deviation of 7.69, mean deviation of 5.46, and Risk Adjusted Performance of (0.16). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Marker Therapeutics, as well as the relationship between them. Please verify Marker Therapeutics market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Marker Therapeutics is priced some-what accurately, providing market reflects its recent price of 1.28 per share. Given that Marker Therapeutics is a hitting penny stock territory we strongly suggest to closely look at its jensen alpha.

Marker Therapeutics Price Movement Analysis

Marker Therapeutics Insider Trading Activities

Marker Therapeutics Outstanding Bonds

Marker Therapeutics Predictive Daily Indicators

Marker Therapeutics Forecast Models

Marker Therapeutics' time-series forecasting models are one of many Marker Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Marker Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Marker Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Marker shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Marker Therapeutics. By using and applying Marker Stock analysis, traders can create a robust methodology for identifying Marker entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Marker analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Marker analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Marker Therapeutics stock analysis indicators help investors evaluate how Marker Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Marker Therapeutics shares will generate the highest return on investment. By understating and applying Marker Therapeutics stock analysis, traders can identify Marker Therapeutics position entry and exit signals to maximize returns.

When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.